← Back to home

RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATIONS/TFE3 GENE FUSIONS

Clinical trials for RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATIONS/TFE3 GENE FUSIONS explained in plain language.

Never miss a new study

Get alerted when new RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATIONS/TFE3 GENE FUSIONS trials appear

Sign up with your email to follow new studies for RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATIONS/TFE3 GENE FUSIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Head-to-Head drug trial for Tough-to-Treat kidney cancer

Disease control Ongoing

This study compares two existing drugs, cabozantinib and sunitinib, for patients with advanced, rare types of kidney cancer that have spread. The goal is to see which drug is better at controlling the cancer's growth and which has fewer side effects. Participants are randomly ass…

Matched conditions: RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATIONS/TFE3 GENE FUSIONS

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Apr 03, 2026 14:42 UTC

RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATIONS/TFE3 GENE FUSIONS

Get alerted when new RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATIONS/TFE3 GENE FUSIONS trials appear

Head-to-Head drug trial for Tough-to-Treat kidney cancer